Abstract
Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Current Pharmaceutical Design
Title: Tissue Transport of Anti-cancer Drugs
Volume: 8 Issue: 22
Author(s): Jan Lankelma
Affiliation:
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Abstract: Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Export Options
About this article
Cite this article as:
Lankelma Jan, Tissue Transport of Anti-cancer Drugs, Current Pharmaceutical Design 2002; 8 (22) . https://dx.doi.org/10.2174/1381612023393512
DOI https://dx.doi.org/10.2174/1381612023393512 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Cationic Liposome Mediated Delivery of FUS1 and hIL-12 Coexpression Plasmid Demonstrates Enhanced Activity against Human Lung Cancer
Current Cancer Drug Targets Targeted Regulation of PI3K/Akt/mTOR/NF-κB Signaling by Indole Compounds and their Derivatives: Mechanistic Details and Biological Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Oral Precancerous Lesions Show Increased Levels of Glutathione Compared to Cancerous Tissue
Current Nutrition & Food Science Fentanyl for Breakthrough Cancer Pain: Where are We?
Reviews on Recent Clinical Trials Histone Deacetylase Inhibitors: Molecular and Biological Activity as a Premise to Clinical Application
Current Drug Metabolism The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins
Current Gene Therapy Stem Cell Function, Self-Renewal, Heterogeneity, and Regenerative Potential in Skeletal Muscle Stem Cells
Recent Patents on Regenerative Medicine Protein Transduction Domains: Applications for Molecular Medicine
Current Gene Therapy Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
Current Drug Targets Ototoxicity: Mechanisms of Cochlear Impairment and its Prevention
Current Medicinal Chemistry MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Recent Trends in Targeted Anticancer Prodrug and Conjugate Design
Current Medicinal Chemistry Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design